Haroon Mokhtarzada
Angel investor in Washington
Washington, District of Columbia
Haroon Mokhtarzada, Angel investor in Washington is an active investor based in Washington, District of Columbia. This profile covers what Haroon Mokhtarzada backs, at which stage, and how founders can reach out in 2026.
Mr. Haroon Mokhtarzada is a Co-Founder at Mokhtarzada Hatchery. Mr. Mokhtarzada serves as Board Member at Bellhop. He co-founded and served as Chief Executive Officer, Chief Product Officer & Chairman at Truebill. He serves as a Board Member at SamCart. He serves as a Board Member at Wahid. He serves as Board Member at Range. He co-founded Webs and served as Vice President of Digital Products at Web's parent company, Vistaprint. He is a Board member at Fieldbook. He has a passion for technology startups, innovation, and entrepreneurship. In addition to his current role at Vistaprint, he continues to engage with startups as an Advisor and Angel Investor to a variety of consumer web and mobile technology companies. He also serves on American Express Open's Digital Advisory Board and is a Member of the United Nations Foundation Global Entrepreneurs Council. As CEO of Webs, he led several key product launches including the creation of the Social Gaming Network, which was spun out of Webs in 2008, and Pagemodo, a social marketing suite for small businesses. In 2011, Webs was acquired by Vistaprint. He holds a JD (Doctor of Law) in Law from Harvard Law School and a BA (Bachelor of Arts) in Economics from the University of Maryland, College Park.
- Investor type
- Angel
- Stages
- Early Stage VentureSeedLate Stage Venture
- Invests in
- Healthcare & BiotechSaaS & EnterpriseClimate & EnergyEdTechMedia & ContentImpact & Social Enterprise
- Location
- Washington, District of Columbia
- Typical check
- $500K
- Past investments
- 12
Notable investments
BoatboundAmplemarket
Buy Me a CoffeeWellplaece
Grow Credit
Keen Home
Substack
ImmediatelyLetterCommunity Foundation of Montgomery CountyReflection ParkTrustworthyHow to reach Haroon Mokhtarzada
Angels and operators like Haroon Mokhtarzada reply to specific, personalized notes that show real traction, not mass blasts. Build a verified list, write a note that fits their thesis, and track replies, all on Round Funded.
Reach active investors like this one
About this profile
This profile is part of Round Funded, an investor database and outreach platform for founders. It covers 60,000+ active VCs, angels, family offices and accelerators with verified contacts, lets you send pitches from your own Gmail, and includes a free Data Room for your raise. How this data is built.
Cite this page
Round Funded. "Haroon Mokhtarzada." Round Funded investor database, updated September 8, 2026.
Stable URL, it will not change: https://www.roundfunded.com/en/investor/haroon-mokhtarzada-106125-7
Frequently Asked Questions
What does Haroon Mokhtarzada invest in?
Haroon Mokhtarzada invests in Healthcare & Biotech, SaaS & Enterprise, Climate & Energy and EdTech, typically at Early Stage Venture, Seed and Late Stage Venture. Match your sector and stage, then reach out with a personalized pitch.
What stage does Haroon Mokhtarzada invest at?
Haroon Mokhtarzada typically invests at Early Stage Venture, Seed and Late Stage Venture. Lead with traction that fits the stage when you reach out.
What is Haroon Mokhtarzada's typical check size?
Haroon Mokhtarzada typically writes checks around $500K. Use it as a signal for whether your raise fits their stage.
How do founders reach investors like this?
Round Funded lists active investors with verified, professional contact details for signed-up founders. Filter by sector, stage and location, then send a personalized pitch from your own inbox.
What is Round Funded?
Round Funded is an investor database and outreach platform for startup founders. It lists 60,000+ active investors with verified contacts, filtered to recent investment activity, and lets founders send personalized pitches from their own Gmail, track replies, and share a free Data Room. Round+ starts at $99 per month with a 3-day trial.